logo-loader

Pfizer says rheumatoid arthritis treatment shows improvement

Last updated: 13:01 21 Sep 2015 EDT, First published: 11:01 21 Sep 2015 EDT

drug_research_v2_350_56001c424e3d8
Pfizer's rheumatoid arthritis shows improvement.

Pfizer (NYSE:PFE) rose in morning trades after the biopharmaceutical company said its rheumatoid arthritis treatment showed improvement in two late-stage clinical studies for the treatment of ulcerative colitis.

Pfizer edged up 1.2% to $33.24 at 10:51 a.m. in New York, expanding this year’s gain to 6.7%.

Both studies met their primary endpoints, the New York-based company said in a statement on Monday.

“We are encouraged by the results of the OCTAVE [Oral Clinical Trials for tofAcitinib in ulceratiVE colitis] induction studies as ulcerative colitis is a chronic, and at times debilitating, disease that can be difficult to treat” Rory O’Connor, head of the company’s global medical affairs was quoted in the statement as saying.

 


Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

1 hour, 11 minutes ago